GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » EV-to-Revenue

EBS (Emergent BioSolutions) EV-to-Revenue : 0.94 (As of Jun. 12, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Emergent BioSolutions's enterprise value is $878.6 Mil. Emergent BioSolutions's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $930.3 Mil. Therefore, Emergent BioSolutions's EV-to-Revenue for today is 0.94.

The historical rank and industry rank for Emergent BioSolutions's EV-to-Revenue or its related term are showing as below:

EBS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8   Med: 3.74   Max: 6.64
Current: 0.94

During the past 13 years, the highest EV-to-Revenue of Emergent BioSolutions was 6.64. The lowest was 0.80. And the median was 3.74.

EBS's EV-to-Revenue is ranked better than
81.81% of 973 companies
in the Drug Manufacturers industry
Industry Median: 2.47 vs EBS: 0.94

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-12), Emergent BioSolutions's stock price is $6.60. Emergent BioSolutions's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $16.96. Therefore, Emergent BioSolutions's PS Ratio for today is 0.39.


Emergent BioSolutions EV-to-Revenue Historical Data

The historical data trend for Emergent BioSolutions's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions EV-to-Revenue Chart

Emergent BioSolutions Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.43 1.52 1.26 0.85 1.07

Emergent BioSolutions Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 1.07 0.88 1.07 0.84

Competitive Comparison of Emergent BioSolutions's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's EV-to-Revenue falls into.


;
;

Emergent BioSolutions EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Emergent BioSolutions's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=878.633/930.3
=0.94

Emergent BioSolutions's current Enterprise Value is $878.6 Mil.
Emergent BioSolutions's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $930.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Emergent BioSolutions  (NYSE:EBS) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Emergent BioSolutions's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6.60/16.963
=0.39

Emergent BioSolutions's share price for today is $6.60.
Emergent BioSolutions's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.96.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Emergent BioSolutions EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions Business Description

Traded in Other Exchanges
Address
300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Executives
Keith Katkin director C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Neal Franklin Fowler director C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Donald W Degolyer director 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Marvin L White director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
William Hartzel officer: SVP, Bioservices 400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii officer: Interim CEO EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Paul Anthony Williams officer: SVP, Products Business 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal director C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Glessner Coleen officer: EVP, Quality & Ethics, and CPL 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox officer: EVP, Ext Aff, GC, Corp Sec 400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl officer: EVP, Chief Financial Officer NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey officer: EVP, BioDefense Division 2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853